Carisma Therapeutics Inc (CARM)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Thomas R. Cannell
Employees:
20
3675 MARKET STREET, SUITE 200, PHILADELPHIA, PA, 19104
2674916422

Carisma Therapeutics Inc. a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) Its lead product candidates include Vicineum, which is in Phase III clinical trials for the treatment of bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer. The company was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Data derived from most recent annual or quarterly report
Market Cap 1.475 Billion Shares Outstanding203.492 Million Avg 30-day Volume 187.243 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS3.46
Price to Revenue0.9342 Debt to Equity0.0 EBITDA-37.722 Million
Price to Book Value0.4604 Operating Margin-91.2873 Enterprise Value-99.338 Million
Current Ratio6.728 EPS Growth1.673 Quick Ratio6.471
1 Yr BETA -0.4471 52-week High/Low 7.4 / 0.37 Profit Margin-109.7192
Operating Cash Flow Growth-123.0711 Altman Z-Score-0.8853 Free Cash Flow to Firm 28.777 Million
Earnings Report2023-08-07
View SEC Filings from CARM instead.

View recent insider trading info

Carisma Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding CARM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding CARM

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 3: filed on 2023-03-13 by MODERNATX, INC.
  • 4: filed on 2023-02-23 by SULLIVAN MARK
  • 4: filed on 2023-02-23 by RYU ELLY
  • 4: filed on 2023-02-23 by CANNELL THOMAS R
  • 4: filed on 2023-02-23 by FORBES MONICA
  • 4: filed on 2023-02-23 by MACDONALD GLEN C
  • 4: filed on 2022-06-24 by DUKER JAY S.
  • 4: filed on 2022-06-24 by HONIG PETER
  • 4: filed on 2022-06-24 by JEWETT MICHAEL A. S.
  • 4: filed on 2022-06-24 by KEYES JASON A

    • Events (8k)

  • 8-K: filed on 2023-05-12:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2023-04-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-08:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.01: Completion of Acquisition or Disposition of Assets
    Item 3.02: Unregistered Sales of Equity Securities
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 4.01: Changes in Registrant's Certifying Accountant
    Item 5.01: Changes in Control of Registrant
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-06:
    Item 8.01: Other Events
  • 8-K: filed on 2023-03-02:
    Item 3.03: Material Modifications to Rights of Security Holders
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-28:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-27:
    Item 8.01: Other Events
  • 8-K: filed on 2023-02-14:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-07:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    ZWEIFACH SANFORD S

    • Director
    		 0 2023-03-07 2

    KELLY STEVEN PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2023-03-07 2

    MORRIS RICHARD STEVEN CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-03-07 2

    ODLANDER BJORN

    • Director
    		 0 2023-03-07 1

    MORRISON BRIGGS

    • Director
    		 0 2023-03-07 2

    UGWUMBA CHIDOZIE

    • Director
    		 0 2023-03-07 2

    MODERNATX, INC.

    • 10% Owner
    		 5,059,338 2023-03-07 1

    KLICHINSKY MICHAEL CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2023-03-07 2

    TOROK MICHAEL

    • Director
    		 0 2023-03-07 2

    HODITS REGINA

    • Director
    		 0 2023-03-07 2

    SULLIVAN MARK GENERAL COUNSEL & SECRETARY

    • Officer
    		 378,651 2023-03-02 2

    CANNELL THOMAS R PRESIDENT AND CEO

    • Officer
    • Director
    		 672,386 2023-03-02 2

    FORBES MONICA CHIEF FINANCIAL OFFICER

    • Officer
    		 505,664 2023-03-02 2

    MACDONALD GLEN C CHIEF TECHNOLOGY OFFICER

    • Officer
    		 398,918 2023-03-02 2

    RYU ELLY PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 148,624 2023-03-02 2

    HONIG PETER

    • Director
    		 105,000 2022-06-22 1

    DUKER JAY S.

    • Director
    		 105,000 2022-06-22 1

    BOURDOW CARRIE L.

    • Director
    		 105,000 2022-06-22 1

    KEYES JASON A

    • Director
    		 105,000 2022-06-22 1

    JEWETT MICHAEL A. S.

    • Director
    		 105,000 2022-06-22 1

    ROSALES MINORI CHIEF DEVELOPMENT OFFICER

    • Officer
    		 0 2022-01-24 0

    DRAKE PATRICIA M. CHIEF COMMERCIAL OFFICER

    • Officer
    		 1,000,000 2021-06-01 0

    HENDERSON JANE

    • Director
    		 92,500 2021-05-03 0

    ANDERSON KIRSTIN PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 50,000 2021-02-19 0

    LYNCH DANIEL

    • Director
    		 0 2019-06-19 0

    DAN LESLIE

    • Director
    		 0 2019-06-19 0

    DIXON WENDY L

    • Director
    		 0 2019-06-19 0

    FITZGERALD RICHARD F CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2019-02-21 0

    KIM DENNIS CHIEF MEDICAL OFFICER

    • Officer
    		 0 2018-12-03 0

    HURLY STEPHEN A PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2018-06-12 0

    CHANEY PAUL G

    • Director
    		 0 2018-06-12 0

    CELNIKER ABBIE

    • Director
    		 0 2018-06-12 0

    GERTZ BARRY

    • Director
    		 0 2017-05-19 0

    MCCABE JOHN J CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2017-04-03 0

    DECILLIS ARTHUR CHIEF MEDICAL OFFICER

    • Officer
    		 0 2017-04-03 0

    FLAGSHIP VENTURES FUND IV, L.P.

    FLAGSHIP VENTURES FUND 2007, L.P.

    FLAGSHIP VENTURES FUND IV-RX, L.P.

    FLAGSHIP VENTURES 2007 GENERAL PARTNER LLC

    FLAGSHIP VENTURES FUND IV GENERAL PARTNER LLC

    AFEYAN NOUBAR

    KANIA EDWIN M JR

    • 10% Owner
    		 No longer subject to file 2016-09-22 0

    CLAIRMARK INVESTMENTS LTD.

    • 10% Owner
    		 3,582,328 2016-09-20 0

    TUBRIDY KAREN L CHIEF DEVELOPMENT OFFICER

    • Officer
    		 0 2016-07-09 0

    BOXER CAPITAL, LLC

    BOXER ASSET MANAGEMENT INC.

    LEWIS JOSEPH

    MVA INVESTORS, LLC

    • 10% Owner
    		 No longer subject to file 2016-06-13 0

    BERRY DAVID A

    • Director
    		 0 2016-06-08 0

    PFEFFER CARY

    • Director
    		 0 2016-06-08 0

    FURFINE ERIC STEVEN CHIEF SCIENTIFIC OFFICER

    • Officer
    		 34,648 2015-12-28 0

    JAFCO SUPER V3 INVESTMENT LIMITED PARTNERSHIP

    • 10% Owner
    		 No longer subject to file 2015-05-08 0

    PERRY GREGORY D CHIEF FINANCIAL AND BUSINESS

    • Officer
    		 0 2015-02-26 0

    LEVIN MARK J

    • Director
    		 0 2014-03-20 0

    AFEYAN NOUBAR

    • Director
    		 0 2014-03-20 0

    THIRD ROCK VENTURES LP

    THIRD ROCK VENTURES GP, L.P.

    TRV GP, LLC

    STARR KEVIN P

    TEPPER ROBERT I

    LEVIN MARK J

    • Director
    • 10% Owner
    		 4,841,591 2014-02-11 0

    STARR KEVIN P

    TEPPER ROBERT I

    • 10% Owner
    		 330,708 2014-02-05 0

    THIRD ROCK VENTURES LP

    THIRD ROCK VENTURES GP, L.P.

    TRV GP, LLC

    • 10% Owner
    		 330,708 2014-02-05 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CARISMA THERAPEUTICS INC CARM 2023-06-07 22:15:04 UTC 3.3094 1.7606 200000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 21:45:05 UTC 3.3094 1.7606 200000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 21:15:04 UTC 3.3094 1.7606 200000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 20:45:04 UTC 3.3094 1.7606 200000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 20:15:06 UTC 3.3094 1.7606 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 19:45:04 UTC 3.3094 1.7606 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 19:15:04 UTC 3.3094 1.7606 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 18:45:04 UTC 3.3094 1.7606 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 18:15:03 UTC 3.3094 1.7606 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 17:45:05 UTC 3.3094 1.7606 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 17:15:04 UTC 3.3094 1.7606 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 16:45:03 UTC 3.3384 1.7316 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 16:15:04 UTC 3.3384 1.7316 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 15:45:04 UTC 3.3384 1.7316 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 15:15:04 UTC 3.3384 1.7316 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 14:45:04 UTC 3.3384 1.7316 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 14:15:03 UTC 3.3384 1.7316 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 13:45:03 UTC 2.9444 2.1256 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 13:15:04 UTC 2.9444 2.1256 250000
    CARISMA THERAPEUTICS INC CARM 2023-06-07 12:45:04 UTC 2.9444 2.1256 250000

    Current Active Short Positions

    Get more info on our International short position coverage here

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund CARM -25568.0 shares, $0.0 2023-03-31 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund CARM -1678.0 shares, $-5201.8 2023-03-31 N-PORT
    Henderson Global Investors Limited Sesen Bio, Inc 0.51% 2021-10-20 GERMANY

    Short Position History (International Only)

    Holder Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments